Compare Stocks

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CHFS Nuwellis	$0.26 -7.1%	$4.79	$4.86 ▼ $37.50	$1.57M	1.55	467,323 shs	526,291 shs
EYES Second Sight Medical Products		$5.67	$3.42 ▼ $12.72	$54.38M	2.55	132,982 shs	36,800 shs
NDRA ENDRA Life Sciences	$0.23	$0.88	$0.22 ▼ $2.79	$2.55M	0.98	295,884 shs	58,339 shs

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CHFS Nuwellis	-6.26%	-32.82%	-42.26%	-42.27%	-94.07%
EYES Second Sight Medical Products	0.00%	0.00%	0.00%	0.00%	0.00%
NDRA ENDRA Life Sciences	+2.32%	-36.92%	-77.98%	-78.59%	-85.85%

Now Open: Crypto emergency update (Ad)

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CHFS Nuwellis	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EYES Second Sight Medical Products	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NDRA ENDRA Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CHFS Nuwellis	N/A	N/A	N/A	N/A
EYES Second Sight Medical Products	N/A	N/A	N/A	N/A
NDRA ENDRA Life Sciences	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CHFS Nuwellis	$5.51M	0.29	N/A	N/A	$12.79 per share	0.02
EYES Second Sight Medical Products	$3.38M	0.00	N/A	N/A	$4.80 per share	0.00
NDRA ENDRA Life Sciences	N/A	N/A	N/A	N/A	$0.67 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CHFS Nuwellis	-$18.11M	-$279.28	N/A	N/A	N/A	-254.26%	-173.61%	-131.01%	N/A
EYES Second Sight Medical Products	-$8.92M	N/A	0.00	N/A	N/A	N/A	-13.58%	-13.02%	N/A
NDRA ENDRA Life Sciences	-$10.06M	-$1.93	N/A	∞	N/A	N/A	-197.36%	-144.22%	5/20/2024 (Estimated)

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CHFS Nuwellis	N/A	N/A	N/A	N/A	N/A
EYES Second Sight Medical Products	N/A	N/A	N/A	N/A	N/A
NDRA ENDRA Life Sciences	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CHFS Nuwellis	N/A	6.87	5.97
EYES Second Sight Medical Products	N/A	22.15	22.15
NDRA ENDRA Life Sciences	N/A	6.26	3.36

Ownership

Institutional Ownership

Company	Institutional Ownership
CHFS Nuwellis	65.06%
EYES Second Sight Medical Products	N/A
NDRA ENDRA Life Sciences	1.19%

Insider Ownership

Company	Insider Ownership
CHFS Nuwellis	0.60%
EYES Second Sight Medical Products	47.20%
NDRA ENDRA Life Sciences	4.80%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CHFS Nuwellis	66	6.04 million	N/A	Not Optionable
EYES Second Sight Medical Products	15	13.14 million	6.94 million	Optionable
NDRA ENDRA Life Sciences	21	11.04 million	10.51 million	Not Optionable

EYES, NDRA, and CHFS Headlines

Source	Headline
	Life sciences push brings new partner to Orrick managingip.com - April 16 at 7:04 PM
	IRA Capital Acquires 237,000 Square-Foot Life Science/R&D Campus in Columbus markets.businessinsider.com - April 12 at 1:52 PM
	Survey: Life Sciences Incubators Anticipate Continued Growth businessfacilities.com - April 10 at 2:00 PM
	ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q4 2023 Earnings Call Transcript finance.yahoo.com - April 1 at 5:56 PM
	Q4 2023 ENDRA Life Sciences Inc Earnings Call finance.yahoo.com - March 29 at 8:47 AM
	ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update businesswire.com - March 28 at 4:05 PM
	Earnings Preview For ENDRA Life Sciences benzinga.com - March 27 at 2:48 PM
	Ernest Pharmaceuticals Wins Lever's Western Mass Health Technology Challenge iberkshires.com - March 24 at 11:02 PM
	ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024 finance.yahoo.com - March 21 at 10:37 AM
	Report: 2024 U.S. Life Sciences Salary Trends biospace.com - March 19 at 12:51 AM
	Life Science Analytics Market Surges to US$ 68.6 Billion by 2032 with 10.7% CAGR fmiblog.com - March 18 at 2:53 AM
	The Boston area built a ton of lab space. Now many of those buildings are opening empty statnews.com - March 16 at 7:06 PM
	Nuclera appoints Joseph Bertelsen as Chief Commercial Officer msn.com - March 14 at 3:01 PM
	SCBio launches new life sciences business accelerator program upstatebusinessjournal.com - March 7 at 1:33 PM
	Life sciences companies need more than just scientists bizjournals.com - March 6 at 4:32 PM
	ENDRA installs first TAEUS liver system at London hospital msn.com - February 28 at 2:21 PM
	ENDRA Life Sciences Installs First TAEUS System in the UK finance.yahoo.com - February 27 at 9:48 AM
	ENDRA Life Sciences Installs First TAEUS System in the UK businesswire.com - February 27 at 8:00 AM
	New findings suggest life span can be increased by making cells less efficient at producing energy msn.com - February 23 at 12:49 PM
	New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences’ TAEUS System finance.yahoo.com - February 21 at 12:56 PM
	New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences' TAEUS System businesswire.com - February 21 at 8:00 AM
	ENDRA Life Sciences Inc (NDRA) investing.com - February 21 at 2:13 AM
	ENDRA Life Sciences secures new patents for ultrasound tech investing.com - February 17 at 12:56 AM
	ENDRA Life Sciences Inc. wsj.com - February 15 at 10:41 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Nuwellis

NASDAQ:CHFS

Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.

Second Sight Medical Products

NASDAQ:EYES

Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.

ENDRA Life Sciences

NASDAQ:NDRA

ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial